Key result
Study protocol evaluates circulating anti-TREK-1 autoantibodies in short-coupled ventricular fibrillation without reporting results.
Why the study?
Are circulating autoantibodies targeting TREK-1 present in patients with short-coupled ventricular fibrillation and do they play a role in arrhythmogenesis?
Observational
Are circulating autoantibodies targeting TREK-1 present in patients with short-coupled ventricular fibrillation and do they play a role in arrhythmogenesis?
Answers are grounded in this paper and cite their sources.
This study investigates the novel hypothesis that autoimmune mechanisms, specifically autoantibodies targeting TREK-1, may contribute to the pathogenesis of short-coupled ventricular fibrillation.
Short-coupled ventricular fibrillation (SCVF) is increasingly being recognized as a distinct primary electrical disorder and cause of otherwise unexplained cardiac arrest. However, the pathophysiology of SCVF remains largely elusive. Despite extensive genetic screening, there is no convincing evidence of a robust monogenic disease gene, thus raising the speculations for alternative pathogeneses. The role of autoimmune mechanisms in SCVF has not been investigated so far. The objective of this study was to screen for circulating autoantibodies in patients with SCVF and assess their role in arrhythmogenesis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted an observational in Short-coupled ventricular fibrillation (SCVF). Circulating autoantibodies targeting TREK-1 was evaluated on Presence of circulating autoantibodies and their role in arrhythmogenesis. The abstract outlines a study to screen for circulating autoantibodies targeting TREK-1 in patients with short-coupled ventricular fibrillation, but reports no results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: